MedPath

The effect of high dose cholecalciferol orally on serum of vitamin D in elderly with osteoarthritis of the hip

Phase 4
Withdrawn
Conditions
Vitamin D deficiency
10013296
Registration Number
NL-OMON37463
Lead Sponsor
Reinier de Graaf Groep
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Withdrawn
Sex
Not specified
Target Recruitment
80
Inclusion Criteria

1. Informed consent signed by patient;2. Male and female patients aged 70 years and older;3. Diagnoses of osteoarthritis of the hip.;4. Baseline level of serum 25-OHD <100 nmol/liter ;5. For inclusion in the conservative treatment group: Patients having osteoarthritis of the hip, which will be treated conservative.;6. For inclusion in the operative group: Patients having disabling osteoarthritis of the hip and scheduled for elective total hip surgery.

Exclusion Criteria

1. Unwillingness to cooperate with the study procedures;2. History of an active malignancy ;3. Quetelet index (QI=weight in (kilogram)/ squire length (meters)) >40;4. History of chronic kidney disease (glomerular filtration rate (GFR) <20ml/min, calculated with Cockcroft-Gault equations);5. History of primary hyperparathyroidism;6. History of sarcoidosis;7. Serum calcium corrected for serum albumin above 2.65nmol/l

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>The effect of different doses cholecalciferol on serum 25-OHD</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>- To determine the effect of 150,000 vs 300,000 IU cholecalciferol on serum<br /><br>calcium and PTH on day 3, 5, 14 and after 6 weeks and 3 months<br /><br>- To determine the effect of surgery on the absorption of cholecalciferol<br /><br>- To determine the effect of surgery on serum calcium and PTH<br /><br>- To determine whether there is a wash-out period of the effect of<br /><br>cholecalciferol during 3 months of follow up, i.e. what is the time serum<br /><br>25-OHD is remains above 50nmol/liter after a single oral dose of<br /><br>cholecalciferol.<br /><br>- To determine changes in general well being measured by SF-12.<br /><br>- To determine whether there is relapse of patients from sufficient to<br /><br>insufficient or deficient</p><br>
© Copyright 2025. All Rights Reserved by MedPath